Decreased motivational properties of morphine in mouse models of cancerous- or inflammatory-chronic pain: Implication of supraspinal neuropeptide FF2 receptors

Neuroscience

Volumn 157, Issue 1, 2008, Pages 12-21

  Betourne, A ^a   Familiades, J ^a   Lacassagne, L ^a   Halley, H ^a   Cazales, M ^b   Ducommun, B ^b   Lassalle, J M ^a   Zajac, J M ^b   Frances, B ^a  

^a Université Paul Sabatier   (France)

^b UNIVERSITÉ DE TOULOUSE   (France)

Author keywords

cancer pain; conditioned place preference; inflammatory pain; morphine; neuropeptide FF; reward

Indexed keywords

CARRAGEENAN; FREUND ADJUVANT; MORPHINE; NEUROPEPTIDE FF; NEUROPEPTIDE RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRAIN REGION; CANCER PAIN; CHRONIC PAIN; CONTROLLED STUDY; FEMALE; HINDLIMB; INFLAMMATION; LOCOMOTION; MELANOMA CELL; MOTIVATION; MOUSE; NOCICEPTION; NONHUMAN; NUCLEUS ACCUMBENS; PLACE PREFERENCE; PRIORITY JOURNAL; REWARD;

ANALGESICS, OPIOID; ANIMALS; AUTORADIOGRAPHY; BEHAVIOR, ANIMAL; CHRONIC DISEASE; CONDITIONING, OPERANT; EDEMA; FEMALE; FOOT; INFLAMMATION; MICE; MICE, INBRED C57BL; MORPHINE; MOTIVATION; MOTOR ACTIVITY; NEOPLASMS; PAIN; PAIN MEASUREMENT; RECEPTORS, NEUROPEPTIDE;

EID: 54549091970     PISSN: 03064522     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuroscience.2008.08.045     Document Type: Article

References (64)

1. Ballantyne J.C., and LaForge K.S. Opioid dependence and addiction during opioid treatment of chronic pain. Pain 129 (2007) 235-255
2. Bardo M.T., and Bevins R.A. Conditioned place preference: what does it add to our preclinical understanding of drug reward?. Psychopharmacology 153 (2000) 31-43
3. Brunjes P.C., Illig K.R., and Meyer E.A. A field guide to the anterior olfactory nucleus (cortex). Brain Res Brain Res Rev 50 (2005) 305-335
4. Cenquizca L.A., and Swanson L.W. Spatial organization of direct hippocampal field CA1 axonal projections to the rest of the cerebral cortex. Brain Res Rev 56 (2007) 1-26
5. Dubuisson D., and Dennis S.G. The formalin test: a quantitative study of the analgesic effects of morphine, meperidine, and brain stem stimulation in rats and cats. Pain 4 (1977) 161-174
6. Evans P.J. Narcotic addiction in patients with chronic pain. Anaesthesia 36 (1981) 597-602
7. Fallon J.H., Riley J.N., Sipe J.C., and Moore R.Y. The islands of Calleja: organization and connections. J Comp Neurol 181 (1978) 375-395
8. Fang Q., Wang Y.Q., He F., Guo J., Guo J., Chen Q., and Wang R. Inhibition of neuropeptide FF (NPFF)-induced hypothermia and anti-morphine analgesia by RF9, a new selective NPFF receptors antagonist. Regul Pept 147 (2008) 45-51
9. Fidler I.J. Biological behavior of malignant melanoma cells correlated to their survival in vivo. Cancer Res 35 (1975) 218-224
10. Franklin K.B.J., and Paxinos G. The mouse brain in stereotaxic coordinates (1997), Elsevier Academic Press, Amsterdam
11. Friedman R., Li V., and Mehrotra D. Treating pain patients at risk: evaluation of a screening tool in opioid-treated pain patients with and without addiction. Pain Med 4 (2003) 182-185
12. Furlan A.D., Sandoval J.A., Mailis-Gagnon A., and Tunks E. Opioids for chronic noncancer pain: a meta-analysis of effectiveness and side effects. CMAJ 174 (2006) 1589-1594
13. Geisler S., and Zahm D.S. Neurotensin afferents of the ventral tegmental area in the rat: [1] re-examination of their origins and [2] responses to acute psychostimulant and antipsychotic drug administration. Eur J Neurosci 24 (2006) 116-134
14. Gelot A., Frances B., Gicquel S., and Zajac J.M. Antisense oligonucleotides to human SQA-neuropeptide FF decrease morphine tolerance and dependence in mice. Eur J Pharmacol 358 (1998) 203-206
15. Gouarderes C., Faura C.C., and Zajac J.M. Rodent strain differences in the NPFF1 and NPFF2 receptor distribution and density in the central nervous system. Brain Res 1014 (2004) 61-70
16. Gouarderes C., Puget A., and Zajac J.M. Detailed distribution of neuropeptide FF receptors (NPFF1 and NPFF2) in the rat, mouse, octodon, rabbit, guinea pig, and marmoset monkey brains: a comparative autoradiographic study. Synapse 51 (2004) 249-269
17. Gouarderes C., Mollereau C., Tafani J.A., Mazarguil H., and Zajac J.M. [125]EYF: a new high affinity radioligand to neuropeptide FF receptors. Peptides 22 (2001) 623-629
18. Gouarderes C., Quelven I., Mollereau C., Mazarguil H., Rice S.Q., and Zajac J.M. Quantitative autoradiographic distribution of NPFF1 neuropeptide FF receptor in the rat brain and comparison with NPFF2 receptor by using [125I]YVP and [(125I]EYF as selective radioligands. Neuroscience 115 (2002) 349-361
19. Henriques M.G., Silva P.M., Martins M.A., Flores C.A., Cunha F.Q., Assreuy-Filho J., and Cordeiro R.S. Mouse paw edema. A new model for inflammation?. Braz J Med Biol Res 20 2 (1987) 243-249
20. Honore P., Rogers S.D., Schwei M.J., Salak-Johnson J.L., Luger N.M., Sabino M.C., Clohisy D.R., and Mantyh P.W. Murine models of inflammatory, neuropathic and cancer pain each generates a unique set of neurochemical changes in the spinal cord and sensory neurons. Neuroscience 98 (2000) 585-598
21. Kersante F., Mollereau C., Zajac J.M., and Roumy M. Anti-opioid activities of NPFF1 receptors in a SH-SY5Y model. Peptides 27 (2006) 980-989
22. Kimura M., Satoh T., and Matsumoto N. What does the habenula tell dopamine neurons?. Nat Neurosci 10 (2007) 677-678
23. Kornetsky C., Huston-Lyons D., and Porrino L.J. The role of the olfactory tubercle in the effects of cocaine, morphine and brain-stimulation reward. Brain Res 541 (1991) 75-81
24. Kotlinska J., Pachuta A., Dylag T., and Silberring J. Neuropeptide FF (NPFF) reduces the expression of morphine- but not of ethanol-induced conditioned place preference in rats. Peptides 28 (2007) 2235-2242
25. Kowianski P., Morys J.M., Wojcik S., Dziewiatkowski J., Luczynska A., Spodnik E., Timmermans J.P., and Morys J. Neuropeptide-containing neurons in the endopiriform region of the rat: morphology and colocalization with calcium-binding proteins and nitric oxide synthase. Brain Res 996 (2004) 97-110
26. Lombard M.C., Weil-Fugazza J., Ries C., and Allard M. Unilateral joint inflammation induces bilateral and time-dependent changes in neuropeptide FF binding in the superficial dorsal horn of the rat spinal cord: implication of supraspinal descending systems. Brain Res 816 (1999) 598-608
27. Malin D.H., Lake J.R., Fowler D.E., Hammond M.V., Brown S.L., Leyva J.E., Prasco P.E., and Dougherty T.M. FMRF-NH2-like mammalian peptide precipitates opiate-withdrawal syndrome in the rat. Peptides 11 (1990) 277-280
28. Mantyh P.W. A mechanism-based understanding of bone cancer pain. Novartis Found Symp 261 (2004) 194-214 discussion 214-219:256-261.
29. Mantyh P.W., Clohisy D.R., Koltzenburg M., and Hunt S.P. Molecular mechanisms of cancer pain. Nat Rev Cancer 2 (2002) 201-209
30. Mao-Ying Q.L., Cui K.M., Liu Q., Dong Z.Q., Wang W., Wang J., Sha H., Wu G.C., and Wang Y.Q. Stage-dependent analgesia of electro-acupuncture in a mouse model of cutaneous cancer pain. Eur J Pain 10 (2006) 689-694
31. Marchand S., Betourne A., Marty V., Daumas S., Halley H., Lassalle J.M., Zajac J.M., and Frances B. A neuropeptide FF agonist blocks the acquisition of conditioned place preference to morphine in C57Bl/6J mice. Peptides 27 (2006) 964-972
32. Menendez L., Lastra A., Fresno M.F., Llames S., Meana A., Hidalgo A., and Baamonde A. Initial thermal heat hypoalgesia and delayed hyperalgesia in a murine model of bone cancer pain. Brain Res 969 (2003) 102-109
33. Mercadante S. Recent progress in the pharmacotherapy of cancer pain. Expert Rev Anticancer Ther 1 (2001) 487-494
34. Miller C.A., and Marshall J.F. Molecular substrates for retrieval and reconsolidation of cocaine-associated contextual memory. Neuron 47 (2005) 873-884
35. Narita M., Kaneko C., Miyoshi K., Nagumo Y., Kuzumaki N., Nakajima M., Nanjo K., Matsuzawa K., Yamazaki M., and Suzuki T. Chronic pain induces anxiety with concomitant changes in opioidergic function in the amygdala. Neuropsychopharmacology 31 (2006) 739-750
36. Narita M., Kishimoto Y., Ise Y., Yajima Y., Misawa K., and Suzuki T. Direct evidence for the involvement of the mesolimbic kappa-opioid system in the morphine-induced rewarding effect under an inflammatory pain-like state. Neuropsychopharmacology 30 (2005) 111-118
37. Narita M., Nakamura A., Ozaki M., Imai S., Miyoshi K., Suzuki M., and Suzuki T. Comparative pharmacological profiles of morphine and oxycodone under a neuropathic pain-like state in mice: evidence for less sensitivity to morphine. Neuropsychopharmacology 33 (2008) 1097-1112
38. Nystedt J.M., Lemberg K., Lintunen M., Mustonen K., Holma R., Kontinen V.K., Kalso E., and Panula P. Pain- and morphine-associated transcriptional regulation of neuropeptide FF and the G-protein-coupled NPFF2 receptor gene. Neurobiol Dis 16 (2004) 254-262
39. Ozaki S., Narita M., Narita M., Iino M., Miyoshi K., and Suzuki T. Suppression of the morphine-induced rewarding effect and G-protein activation in the lower midbrain following nerve injury in the mouse: involvement of G-protein-coupled receptor kinase 2. Neuroscience 116 (2003) 89-97
40. Ozaki S., Narita M., Narita M., Iino M., Sugita J., Matsumura Y., and Suzuki T. Suppression of the morphine-induced rewarding effect in the rat with neuropathic pain: implication of the reduction in mu-opioid receptor functions in the ventral tegmental area. J Neurochem 82 (2002) 1192-1198
41. Ozaki S., Narita M., Narita M., Ozaki M., Khotib J., and Suzuki T. Role of extracellular signal-regulated kinase in the ventral tegmental area in the suppression of the morphine-induced rewarding effect in mice with sciatic nerve ligation. J Neurochem 88 (2004) 1389-1397
42. Passik S.D., Kirsh K.L., Donaghy K.B., and Portenoy R.K. Pain and aberrant drug-related behaviors in medically ill patients with and without histories of substance abuse. Clin J Pain 22 (2006) 173-181
43. Porter J., and Jick H. Addiction rare in patients treated with narcotics. N Engl J Med 302 (1980) 123
44. Ronson A. Psychiatric disorders in oncology: recent therapeutic advances and new conceptual frameworks. Curr Opin Oncol 16 (2004) 318-323
45. Roques B.P. Novel approaches to targeting neuropeptide systems. Trends Pharmacol Sci 21 (2000) 475-483
46. Roumy M., and Zajac J.M. Neuropeptide FF, pain and analgesia. Eur J Pharmacol 345 (1998) 1-11
47. Sallerin-Caute B., Lazorthes Y., Deguine O., Frances B., Verdie J.C., Charlet J.P., and Bastide R. Does intrathecal morphine in the treatment of cancer pain induce the development of tolerance?. Neurosurgery 42 (1998) 44-50
48. Sasamura T., Nakamura S., Iida Y., Fujii H., Murata J., Saiki I., Nojima H., and Kuraishi Y. Morphine analgesia suppresses tumor growth and metastasis in a mouse model of cancer pain produced by orthotopic tumor inoculation. Eur J Pharmacol 441 (2002) 185-191
49. Savage S.R. Long-term opioid therapy: assessment of consequences and risks. J Pain Symptom Manag 11 (1996) 274-286
50. Schwei M.J., Honore P., Rogers S.D., Salak-Johnson J.L., Finke M.P., Ramnaraine M.L., Clohisy D.R., and Mantyh P.W. Neurochemical and cellular reorganization of the spinal cord in a murine model of bone cancer pain. J Neurosci 19 (1999) 10886-10897
51. Shippenberg T.S., Stein C., Huber A., Millan M.J., and Herz A. Motivational effects of opioids in an animal model of prolonged inflammatory pain: alteration in the effects of kappa- but not of mu-receptor agonists. Pain 35 (1988) 179-186
52. Simonin F., Schmitt M., Laulin J.P., Laboureyras E., Jhamandas J.H., MacTavish D., Matifas A., Mollereau C., Laurent P., Parmentier M., Kieffer B.L., Bourguignon J.J., and Simonnet G. RF9, a potent and selective neuropeptide FF receptor antagonist, prevents opioid-induced tolerance associated with hyperalgesia. Proc Natl Acad Sci U S A 103 (2006) 466-471
53. Sufka K.J. Conditioned place preference paradigm: a novel approach for analgesic drug assessment against chronic pain. Pain 58 (1994) 355-366
54. Sufka K.J., Watson G.S., Nothdurft R.E., and Mogil J.S. Scoring the mouse formalin test: validation study. Eur J Pain 2 (1998) 351-358
55. Suzuki T. Mechanism of opioid dependence and interaction between opioid receptors. Eur J Pain 5 Suppl 1 (2001) 63-65
56. Suzuki T., Kishimoto Y., Misawa M., Nagase H., and Takeda F. Role of the kappa-opioid system in the attenuation of the morphine-induced place preference under chronic pain. Life Sci 64 (1999) PL1-PL7
57. Taraschenko O.D., Shulan J.M., Maisonneuve I.M., and Glick S.D. 18-MC acts in the medial habenula and interpeduncular nucleus to attenuate dopamine sensitization to morphine in the nucleus accumbens. Synapse 61 (2007) 547-560
58. Tzschentke T.M. Measuring reward with the conditioned place preference paradigm: a comprehensive review of drug effects, recent progress and new issues. Prog Neurobiol 56 (1998) 613-672
59. Tzschentke T.M. Measuring reward with the conditioned place preference (CPP) paradigm: update of the last decade. Addict Biol 12 (2007) 227-462
60. Wacnik P.W., Eikmeier L.J., Ruggles T.R., Ramnaraine M.L., Walcheck B.K., Beitz A.J., and Wilcox G.L. Functional interactions between tumor and peripheral nerve: morphology, algogen identification, and behavioral characterization of a new murine model of cancer pain. J Neurosci 21 (2001) 9355-9366
61. Yang H.Y., and Iadarola M.J. Activation of spinal neuropeptide FF and the neuropeptide FF receptor 2 during inflammatory hyperalgesia in rats. Neuroscience 118 (2003) 179-187
62. Yang H.Y., and Iadarola M.J. Modulatory roles of the NPFF system in pain mechanisms at the spinal level. Peptides 27 (2006) 943-952
63. Zajac J.M. Neuropeptide FF: new molecular insights. Trends Pharmacol Sci 22 (2001) 63
64. Zimmermann M. Ethical guidelines for investigations of experimental pain in conscious animals. Pain 16 (1983) 109-110